PIPE Proceeds In Hand, Novavax Looks To Score With Two Late-Stage Flu Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
Vaccine-focused biotech says it has sufficient cash to continue business strategy through third-quarter 2009.
You may also be interested in...
Stock Price Increases Suggest Flu-Oriented Biotechs May Capitalize On Differentiation
Companies like Novavax and Dynavax may enjoy improved financial prospects thanks to the way their differentiated approaches to flu therapy could address future outbreaks.
Stock Price Increases Suggest Flu-Oriented Biotechs May Capitalize On Differentiation
Companies like Novavax and Dynavax may enjoy improved financial prospects thanks to the way their differentiated approaches to flu therapy could address future outbreaks.
Novavax Looks To Increase Runway Through Strategic Alliance With India’s Cadila Pharma
A recently announced three-prong partnership with India's Cadila Pharmaceuticals should enable Novavax to pay off $22 million in convertible debt due in July and still have about one year's worth of operating cash, the vaccine maker's chief executive, Rahul Singhvi, said in an interview